Quantcast

Latest autoimmune diseases Stories

2014-09-22 12:26:11

More than $300,000 raised to support research, education and support services for people affected by lupus LOS ANGELES, Sept. 22, 2014 /PRNewswire-USNewswire/ -- Hollywood stars of television turned out to shed light on the cruel mystery that is lupus and raise critically needed funds for research and education programs during the Lupus Foundation of America's (LFA) Walk to End Lupus Now(TM), in Los Angeles on Saturday, September 20, 2014. Walk to End Lupus Now Grand Marshal,...

2014-09-22 08:28:00

Companies Include Silarus Therapeutics Developing Treatments for Anemia and Iron Overload Disorders; and Thyritope Biosciences Developing Treatments for Graves' Orbitopathy SAN DIEGO, Sept. 22, 2014 /PRNewswire/ -- Avalon Ventures today announced the launch of two new companies formed through its collaboration with GlaxoSmithKline (GSK) to fund and launch up to 10 early-stage life science companies. Silarus Therapeutics, Inc. and Thyritope Biosciences, Inc. each will receive up to...

2014-09-22 08:26:16

TOORAK, Australia, Sept. 22, 2014 /PRNewswire/ -- Antisense Therapeutics (the "Company" or "ANP") is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology. The article titled "CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS", is currently available online and will be included in the print edition Volume 83, November 11, 2014. The article highlights the...

2014-09-18 23:03:16

Arthritis Society says patient safety paramount as new class of medications become available Toronto, ON (PRWEB) September 18, 2014 With the arrival of subsequent-entry biologics (SEBs) set to alter the arthritis treatment landscape, The Arthritis Society released new resources to educate stakeholders on their potential impact. The bottom line: safety and strong public policy must guide SEB use, and patients must be well informed when speaking to their healthcare team. Click here for an...

2014-09-18 04:21:05

Company Recently Initiated Phase II in Bullous Pemphigoid CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Sept. 18, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). Dr. Daniel Teper, Chairman and CEO of Immune comments: "Bertilimumab is...

2014-09-17 12:25:34

Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that among Crohn's disease/ulcerative colitis (CD/UC) patients eligible for biologic therapy, only a proportion of patients currently receive a biologic. Surveyed gastroenterologists cite patients' discomfort with biological therapy as the...

2014-09-15 12:27:50

Hundreds Step Up For New Lupus Treatments NEW YORK, Sept. 15, 2014 /PRNewswire/ -- Over 200 patients, families, physicians and scientists came together under one roof Saturday to learn, interact and participate in the drive for better lupus treatments at New York City's first Lupus Trials Fair launched by the Lupus Research Institute (LRI) and the S.L.E. Lupus Foundation. Attendees interacted directly with researchers at eight of NYC's leading institutions -- sharing experiences,...

2014-09-12 08:25:21

- Research grants awarded for five out of more than 200 proposals, highlighting continued commitment to multiple sclerosis (MS) ROCKLAND, Mass., Sept. 12, 2014 /PRNewswire/ -- EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the recipients of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and...

2014-09-11 04:21:10

- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA(®) (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-09-09 12:28:50

Lupus Foundation of America and Rheumatology Research Foundation hold congressional briefing WASHINGTON, Sept. 9, 2014 /PRNewswire-USNewswire/ -- Today, the Lupus Foundation of America, the only national force devoted to solving the mystery of lupus, and the Rheumatology Research Foundation, the largest private funding source of rheumatology research and training programs, convened on Capitol Hill to update our nation's leaders about the new Accelerating Medicines Partnership (AMP)...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related